Humanigen, Inc. (NASDAQ:HGEN) Short Interest Update

Humanigen, Inc. (NASDAQ:HGENGet Rating) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 8,340,000 shares, a growth of 53.6% from the June 30th total of 5,430,000 shares. Based on an average daily trading volume, of 5,720,000 shares, the days-to-cover ratio is presently 1.5 days.

Insider Activity

In other Humanigen news, insider Dale Chappell bought 173,700 shares of the firm’s stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $1.96 per share, for a total transaction of $340,452.00. Following the transaction, the insider now owns 8,066,575 shares of the company’s stock, valued at $15,810,487. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 21.70% of the company’s stock.

Hedge Funds Weigh In On Humanigen

A number of hedge funds and other institutional investors have recently modified their holdings of HGEN. Teacher Retirement System of Texas acquired a new stake in Humanigen in the first quarter valued at approximately $31,000. Pinnacle Associates Ltd. acquired a new stake in Humanigen in the fourth quarter valued at approximately $39,000. ProShare Advisors LLC acquired a new stake in Humanigen in the fourth quarter valued at approximately $40,000. Arizona State Retirement System acquired a new stake in Humanigen in the fourth quarter valued at approximately $48,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Humanigen in the fourth quarter valued at approximately $52,000. 64.34% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HGEN has been the topic of a number of recent analyst reports. Credit Suisse Group lowered shares of Humanigen from a “neutral” rating to an “underperform” rating in a research report on Wednesday, July 13th. Roth Capital lowered shares of Humanigen from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 13th. Cantor Fitzgerald lowered shares of Humanigen from an “overweight” rating to a “neutral” rating in a research report on Wednesday, July 13th. Finally, HC Wainwright lowered shares of Humanigen from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 13th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $24.60.

Humanigen Price Performance

Shares of HGEN stock opened at $0.37 on Friday. The company has a market capitalization of $25.92 million, a P/E ratio of -0.12 and a beta of -0.79. The company’s 50-day simple moving average is $1.79 and its two-hundred day simple moving average is $2.23. Humanigen has a one year low of $0.36 and a one year high of $18.65.

Humanigen (NASDAQ:HGENGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.17. The business had revenue of $1.04 million for the quarter, compared to the consensus estimate of $1.04 million. Humanigen had a negative net margin of 4,640.77% and a negative return on equity of 4,882.88%. On average, research analysts expect that Humanigen will post -1.04 EPS for the current fiscal year.

About Humanigen

(Get Rating)

Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.

Featured Stories

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.